BG Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BGMD research report →
Price Chart
About the company
BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform.
- CEO
- Stephen Hall
- IPO
- 2011
- Employees
- 5
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on BGMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.14K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.30
- Div Yield
- 0.00%
- Gross Margin
- 67.75%
- Op Margin
- -295.66%
- Net Margin
- -338.63%
- ROE
- 747.43%
- ROIC
- -485.83%
Latest fiscal year · YoY change
- Revenue
- $1.57M-43.8%
- Gross Profit
- $1.06M-42.1%
- Op Income
- $-4,630,000
- Net Income
- $-5,303,000+34.2%
- EPS
- $-0.55+44.4%
- OCF Growth
- +55.1%
- FCF Growth
- +55.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.37
- RSI (14)
- 8
- Avg Volume
- 674
No earnings-call transcripts are available for BGMD yet.
- Free Float
- 73.1%
- Shares Outstanding
- 11.37M
- Float Shares
- 8.31M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 5, 16 | Seawell Haygood Paterson Sr | other | 0 |
| May 5, 16 | Seawell Haygood Paterson Sr | other | 0 |
| Apr 14, 14 | Adourian Aram S. | other | 12,000 |
| Apr 14, 14 | Adourian Aram S. | other | 12,000 |
| Mar 31, 16 | SOHMER PAUL R | other | 15,493 |
| Mar 31, 16 | HALL STEPHEN P | other | 8,986 |
| Mar 31, 16 | Adourian Aram S. | other | 7,456 |
| Aug 15, 15 | HALL STEPHEN P | other | 7,530 |
| Aug 15, 15 | Adourian Aram S. | other | 6,233 |
| Feb 4, 16 | LUBER JEFFREY R | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BGMD coverage
Recent articles, reports, and earnings notes.
No research on BGMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BGMD report →Progyny (NASDAQ:PGNY) versus BG Medicine (OTCMKTS:BGMD) Head-To-Head Contrast
defenseworld.net · Mar 31
Critical Comparison: BG Medicine (OTCMKTS:BGMD) and Alignment Healthcare (NASDAQ:ALHC)
defenseworld.net · Dec 30
Ardent Health (NYSE:ARDT) vs. BG Medicine (OTCMKTS:BGMD) Head-To-Head Comparison
defenseworld.net · Dec 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.